Literature DB >> 17058242

Beyond randomized controlled trials: a critical comparison of trials with nonrandomized studies.

Henrik Toft Sørensen1, Timothy L Lash, Kenneth J Rothman.   

Abstract

Observational analogs of randomized clinical trials (RCTs) are well accepted in the study of disease risk factors, diagnosis, and prognosis. There is controversy about observational studies when the focus is on the intended benefit due to lack of blinding and poor control for unmeasured confounding. Well-designed randomized clinical trials are costly both in time and money. Therefore, existing databases are used increasingly and are often the only feasible source with which to examine delayed health effects. We reviewed the reasons for possible discrepancies between RCTs and observational studies. There can be different patient populations, differences in therapeutic regimen, control of confounding, follow-up, measuring outcome, and differences arising from the intention-to-treat analysis. Observational studies cannot replace trials, nor do trials make observational studies unnecessary. Both designs are susceptible to particular bias, so neither provides perfect information.

Entities:  

Mesh:

Year:  2006        PMID: 17058242     DOI: 10.1002/hep.21404

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  65 in total

1.  The lesser known effects of statins: benefits on infectious outcomes may be explained by "healthy user" effect.

Authors:  Reimar W Thomsen
Journal:  BMJ       Date:  2006-11-11

Review 2.  Developments in post-marketing comparative effectiveness research.

Authors:  S Schneeweiss
Journal:  Clin Pharmacol Ther       Date:  2007-06-06       Impact factor: 6.875

3.  Income and recurrent events after a coronary event in women.

Authors:  Krisztina D László; Imre Janszky; Staffan Ahnve
Journal:  Eur J Epidemiol       Date:  2008-09-18       Impact factor: 8.082

Review 4.  Potential and pitfalls of using large administrative claims data to study the safety of osteoporosis therapies.

Authors:  Jie Zhang; Huifeng Yun; Nicole C Wright; Meredith Kilgore; Kenneth G Saag; Elizabeth Delzell
Journal:  Curr Rheumatol Rep       Date:  2011-06       Impact factor: 4.592

5.  Use of oral bisphosphonates and risk of venous thromboembolism: a population-based case-control study.

Authors:  A L Lamberg; E Horvath-Puho; S Christensen; H T Sørensen
Journal:  Osteoporos Int       Date:  2009-12-09       Impact factor: 4.507

6.  Long-Term Survival after Invasive or Conservative Strategy in Elderly Patients with non-ST-Elevation Myocardial Infarction: A Prospective Cohort Study.

Authors:  Kristin Marie Kvakkestad; Jon Michael Gran; Jan Eritsland; Charlotte Holst Hansen; Eigil Fossum; Geir Øystein Andersen; Sigrun Halvorsen
Journal:  Cardiology       Date:  2019-11-05       Impact factor: 1.869

Review 7.  Use of instrumental variable in prescription drug research with observational data: a systematic review.

Authors:  Yong Chen; Becky A Briesacher
Journal:  J Clin Epidemiol       Date:  2010-12-16       Impact factor: 6.437

Review 8.  Osteoporosis therapies: evidence from health-care databases and observational population studies.

Authors:  Stuart L Silverman
Journal:  Calcif Tissue Int       Date:  2010-08-20       Impact factor: 4.333

9.  Medical databases in studies of drug teratogenicity: methodological issues.

Authors:  Vera Ehrenstein; Henrik T Sørensen; Leiv S Bakketeig; Lars Pedersen
Journal:  Clin Epidemiol       Date:  2010-08-09       Impact factor: 4.790

10.  A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies.

Authors:  Jaclyn L F Bosco; Rebecca A Silliman; Soe Soe Thwin; Ann M Geiger; Diana S M Buist; Marianne N Prout; Marianne Ulcickas Yood; Reina Haque; Feifei Wei; Timothy L Lash
Journal:  J Clin Epidemiol       Date:  2009-05-19       Impact factor: 6.437

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.